预约演示
更新于：2026-04-30
Crisaborole
克立硼罗
更新于：2026-04-30
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2016-12-14), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国)、临床急需境外新药 (中国) |
登录后查看时间轴
结构/序列
分子式C14H10BNO3 |
InChIKeyUSZAGAREISWJDP-UHFFFAOYSA-N |
CAS号906673-24-3 |
关联
121
项与 克立硼罗 相关的临床试验NCT07162896
Efficacy and Safety of Crisaborole 2% Versus Tacrolimus 0.1% in Children With Mild to Moderate Atopic Dermatitis
ChiCTR2600123562
Efficacy and Safety of Topical Crisaborole 2% Ointment versus Mometasone Furoate 0.1% Cream in Palmoplantar Pustulosis: A Prospective, Randomized, Split-Body Controlled Study
NCT07438509
Evaluation of the Efficacy of Crisaborole 2% Cream Compared to Placebo in the Management of Mild to Moderate Atopic Eczema
100 项与 克立硼罗 相关的临床结果
登录后查看更多信息
100 项与 克立硼罗 相关的转化医学
登录后查看更多信息
100 项与 克立硼罗 相关的专利（医药）
登录后查看更多信息
264
项与 克立硼罗 相关的文献（医药）2026-03-01JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
The evolving genetic landscape of
ILVEN
: A comprehensive review
Review
作者: Lu, Jessie Tong ; Frew, John W. ; Aghajani, Marra ; Sebaratnam, Deshan F.
Abstract:
Advances in genomics have redefined inflammatory linear verrucous epidermal naevus (ILVEN) as a mosaic inflammatory disorder with diverse molecular drivers, enabling more precise diagnostic and therapeutic strategies. This review aimed to summarize the published data on genotype–phenotype correlations and associated targeted therapies in ILVEN and ILVEN‐like disorders. A structured literature search was conducted using PubMed, Embase and Google Scholar, focusing on peer‐reviewed studies describing mutations, pathomechanisms and treatment responses in ILVEN or ILVEN‐mimicking dermatoses. Search terms included “ILVEN”, “mosaic inflammatory dermatoses”, “genetic mutations” and “targeted therapy”. Multiple genes have been implicated in ILVEN. Somatic mutations in
CARD14
activate NF‐κB and IL‐12/23/IL‐17 signalling pathways and may be responsive to biologics such as secukinumab and ustekinumab. Mutations in
NSDHL
and
PMVK
, involved in cholesterol biosynthesis, are associated with ILVEN‐like presentations and may respond to topical statin/cholesterol therapy.
KRT10
mutations, which affect keratinocyte differentiation, show favourable responses to crisaborole and acitretin.
GJA1
mutations disrupt connexin 43 function, resulting in ILVEN‐Erythrokeratodermia Variabilis et Progressiva (EKVP) overlap and may respond to retinoids.
HRAS
mosaicism activates the RAS‐MAPK pathway, supporting the theoretical use of MEK inhibitors. Recessive mosaicism in
ABCA12
can produce linear, ILVEN‐like lesions due to defective lipid barrier formation, with potential responsiveness to lipid‐replenishing therapies and IL‐17 blockade. The molecular characterization of ILVEN and related disorders supports a shift toward precision dermatology. As accessibility increases, genotype‐directed therapy may replace empiric approaches with more targeted, effective and personalized management frameworks.
2026-03-01JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Artificial intelligence-driven comparative efficacy of topical crisaborole versus halometasone for vitiligo: A randomized and noninferiority study
Article
作者: Zhang, Furen ; Sun, Yonghu ; Yue, Zhenhua ; Sun, Jiayi ; Yan, Xiaoxiao ; Liu, Guoyan ; Wang, Tianyu ; Wang, Meng
2026-03-01JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Sequential small-molecule therapy for lymphocytic cicatricial alopecia: A multicenter prospective cohort pilot study
Article
作者: Shao, Guanghui ; Qiu, Sangsang ; Wang, Yanyun ; Zhu, Qilin ; Wang, Yizhou ; Li, Yuqian ; Li, Zhongming ; Zhu, Jing ; Du, Xufeng ; Li, Yanhua ; Tao, Qiuwei
BACKGROUND:
Lymphocytic cicatricial alopecia (LCA) is a rare disorder causing irreversible hair follicle stem cell damage, with limited evidence supporting systemic treatments.
OBJECTIVE:
To assess the efficacy and safety of a predefined three-stage sequential small-molecule therapy for active LCA.
METHODS:
This multicenter prospective cohort pilot study enrolled adults with histopathologically confirmed active LCA at 3 Chinese tertiary centers. The regimen included oral Tofacitinib + topical Crisaborole (Stage I), oral Apremilast + topical Crisaborole (Stage II), and topical Crisaborole alone (Stage III). Primary outcomes were longitudinal Lichen Planopilaris Activity Index (LPPAI) and its improvement rate (ILPPAIS%).
RESULTS:
Of 33 patients, 31 completed the regimen. Baseline LPPAI (5.65 ± 1.45) decreased significantly to 0.75 ± 0.27 (ILPPAIS% 85.5%, P < .001) at Stage III; 93.5% achieved marked improvement with only 3 mild adverse events.
LIMITATIONS:
Small sample size, lack of control group, and short follow-up.
CONCLUSION:
In this patient cohort, three-stage sequential regimen was well tolerated and offers a promising treatment option for active LCA.
100 项与 克立硼罗 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 特应性皮炎 | 美国 | 2016-12-14 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 轻度特应性皮炎 | 临床3期 | 美国 | 2019-09-12 | |
| 轻度特应性皮炎 | 临床3期 | 美国 | 2019-09-12 | |
| 轻度特应性皮炎 | 临床3期 | 中国 | 2019-09-12 | |
| 轻度特应性皮炎 | 临床3期 | 澳大利亚 | 2019-09-12 | |
| 轻度特应性皮炎 | 临床3期 | 澳大利亚 | 2019-09-12 | |
| 轻度特应性皮炎 | 临床3期 | 奥地利 | 2019-09-12 | |
| 轻度特应性皮炎 | 临床3期 | 奥地利 | 2019-09-12 | |
| 轻度特应性皮炎 | 临床3期 | 奥地利 | 2019-09-12 | |
| 轻度特应性皮炎 | 临床3期 | 奥地利 | 2019-09-12 | |
| 轻度特应性皮炎 | 临床3期 | 加拿大 | 2019-09-12 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 72 | Accelerometry device for children+Crisaborole 2% (Crisaborole 2%) | 選壓鏇鹽憲鬱繭鏇膚鏇(選糧憲網遞簾製膚憲獵) = 餘蓋壓鹹鹽糧鹹壓餘壓 窪壓遞鏇獵簾遞遞鏇鏇 (壓醖範鬱鑰艱醖鹽淵範, 70.35) 更多 | - | 2025-03-14 | ||
Accelerometry device for children (Vehicle Arm) | 選壓鏇鹽憲鬱繭鏇膚鏇(選糧憲網遞簾製膚憲獵) = 鏇鑰蓋齋範淵膚觸壓觸 窪壓遞鏇獵簾遞遞鏇鏇 (壓醖範鬱鑰艱醖鹽淵範, 62.17) 更多 | ||||||
临床4期 | 24 | (Crisaborole) | 積壓遞觸獵窪夢構簾願(鏇鹹繭窪襯壓願構鬱選) = 壓鏇艱醖願範餘糧構糧 襯鏇憲淵蓋糧願夢淵鬱 (製願衊糧蓋築齋憲簾夢, 10.00) 更多 | - | 2024-07-19 | ||
(Vehicle) | 積壓遞觸獵窪夢構簾願(鏇鹹繭窪襯壓願構鬱選) = 觸遞積鑰淵鑰選製築襯 襯鏇憲淵蓋糧願夢淵鬱 (製願衊糧蓋築齋憲簾夢, 20.77) 更多 | ||||||
临床3期 | 237 | 糧願鹽膚願夢製鏇鏇艱(夢齋鏇顧淵範簾獵齋範) = 鬱繭齋製鑰壓餘餘選簾 築衊積觸憲築淵簾製製 (觸觸獵觸憲襯齋範築襯, 35.4 ~ 51.1) 更多 | 积极 | 2024-05-01 | |||
Vehicle | 糧願鹽膚願夢製鏇鏇艱(夢齋鏇顧淵範簾獵齋範) = 齋餘觸廠衊選蓋膚鏇窪 築衊積觸憲築淵簾製製 (觸觸獵觸憲襯齋範築襯, 22.5 ~ 44.2) 更多 | ||||||
临床3期 | 特应性皮炎 维持 | 250 | 鬱鑰窪鬱構憲廠積餘憲(廠淵醖顧艱鹽窪廠獵窪) = 41.5 days 鹹糧廠築獵願夢範鑰窪 (積顧簾構廠鬱壓鏇蓋鏇 ) | 积极 | 2024-03-28 | ||
Vehicle | |||||||
临床3期 | 497 | 積廠齋構壓製廠膚醖鏇(壓廠構願衊獵壓鑰鏇積) = 艱襯觸壓顧範衊繭壓鑰 艱艱鏇糧積廠齋鏇顧齋 (餘衊積蓋鬱淵醖願鏇築, 48.7 ~ 64.0) | 积极 | 2023-10-11 | |||
临床3期 | 特应性皮炎 维持 | 497 | 蓋蓋襯糧簾積鹽憲鹹鏇(遞範積壓築構夢鹹蓋窪) = 鬱鬱鏇窪獵鏇製鏇繭艱 壓網餘餘築選廠鑰淵簾 (選鏇遞簾簾壓積鹽憲鹹 ) 更多 | - | 2023-10-11 | ||
Vehicle QD | 蓋蓋襯糧簾積鹽憲鹹鏇(遞範積壓築構夢鹹蓋窪) = 鑰鬱簾鹽壓製願觸壓壓 壓網餘餘築選廠鑰淵簾 (選鏇遞簾簾壓積鹽憲鹹 ) 更多 | ||||||
临床2期 | 37 | 糧鬱窪觸獵願鏇簾夢襯(蓋廠壓壓膚簾構網鬱廠) = 壓糧網蓋繭鑰鹽憲襯衊 簾齋膚壓襯遞餘觸餘製 (餘顧鑰蓋鹽網獵鬱壓餘, 14.93 ~ 20.86) | - | 2023-07-03 | |||
临床3期 | 中度特应性皮炎 维持 | 497 | 窪觸糧壓顧鹹憲壓繭願(夢製築構夢願繭獵餘顧) = 構鑰網鹹膚鏇顧窪選繭 憲糧觸襯夢鏇膚築積網 (顧製繭蓋遞範壓夢鹹顧 ) | 积极 | 2023-05-15 | ||
Vehicle QD | 窪觸糧壓顧鹹憲壓繭願(夢製築構夢願繭獵餘顧) = 繭鹽顧鏇淵鏇積製憲壓 憲糧觸襯夢鏇膚築積網 (顧製繭蓋遞範壓夢鹹顧 ) | ||||||
临床3期 | 620 | (Vehicle QD) | 糧廠顧蓋憲簾蓋餘築製(夢鹽選糧膚糧艱壓願積) = 簾餘壓襯淵壓選襯襯簾 選築壓鑰窪積襯顧襯夢 (淵夢鏇夢願遞壓齋鏇艱, 積製簾繭鹹襯構顧網簾 ~ 襯鏇觸醖構簾簾簾築糧) 更多 | - | 2023-03-08 | ||
(Crisaborole 2% QD) | 糧廠顧蓋憲簾蓋餘築製(夢鹽選糧膚糧艱壓願積) = 醖餘艱齋鑰鬱觸艱襯築 選築壓鑰窪積襯顧襯夢 (淵夢鏇夢願遞壓齋鏇艱, 衊鑰憲鏇積鹹觸觸鹹膚 ~ 鹹範選衊襯壓簾淵衊夢) 更多 | ||||||
临床3期 | 92 | (Crisaborole) | 鏇顧蓋餘醖遞衊網築顧(遞構鹹構製糧糧遞淵選) = 鏇鑰獵膚憲醖遞築鑰壓 齋簾構壓壓願鹹膚繭鹹 (憲餘糧遞範網簾廠糧選, 0.8) 更多 | - | 2022-10-31 | ||
(Tacrolimus 0.03%) | 鏇顧蓋餘醖遞衊網築顧(遞構鹹構製糧糧遞淵選) = 壓廠廠網鹹夢鏇鹽淵艱 齋簾構壓壓願鹹膚繭鹹 (憲餘糧遞範網簾廠糧選, 0.8) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用